Agitation is a common Alzheimer’s disease symptom, manifesting as pacing and restlessness as well as verbal and physical aggression to family members and caregivers. The drugs used to quell these ...

The FDA has approved Auvelity as the first non-antipsychotic treatment for agitation in Alzheimer's disease, marking a major milestone for patients.

Axsome Therapeutics’ AXSM lead drug, Auvelity (AXS-05), approved for treating major depressive disorder, has witnessed strong sales uptake since its approval and launch. Auvelity, the first approved ...

The U.S. Food and Drug Administration has approved a label expansion for Axsome Therapeutics’ (AXSM) depression therapy Auvelity, allowing its use as a treatment for agitation associated with dementia ...

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host ...

The U.S. Food and Drug Administration has approved the expanded use of Axsome Therapeutics' Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat ...

Axsome Therapeutics AXSM has been witnessing a strong sales uptake for its lead marketed drug, Auvelity (AXS-05), which is approved for treating major depressive disorder. Since its launch in the ...